

Revision date: 11-Oct-2007 Version: 1.3 Page 1 of 10

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Pfizer Ltd

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

**Material Name: Eplerenone Tablets** 

Trade Name: INSPRA; SELARA

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as cardiovascular drug

2. HAZARDS IDENTIFICATION

Appearance: White tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

**Additional Hazard Information:** 

**Short Term:** May cause eye and skin irritation if tablets are crushed or broken (based on components).

Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Effects reported during clinical use include headache, dizziness, decrease in blood pressure

(hypotension), increased potassium, nausea, diarrhea, and insomnia.

EU Indication of danger: Not classified

**Australian Hazard Classification** 

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Version: 1.3

**Hazardous** 

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Eplerenone	107724-20-9	Not listed	Not Listed	25 or 50 mg***
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Ferric oxide red	1309-37-1	215-168-2	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Polyethylene glycol	25322-68-3	Not listed	Not Listed	*
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
		EEC No. 456-230-0		
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Hypromellose	9004-65-3	Not listed	Not Listed	*
Polysorbate 80	9005-65-6	Not listed	Not Listed	*
Ferric oxide yellow	51274-00-1	257-098-5	Not Listed	*
Croscarmellose sodium	74811-65-7	Not listed	Not Listed	*
Lactose	63-42-3	200-559-2	Not Listed	*

Additional Information: \* Proprietary

\*\*\* per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

**Skin Contact:** Remove contaminated clothing and wash exposed area with soap and water. Obtain medical

assistance if irritation occurs.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Not determined

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

# 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Material Name: Eplerenone Tablets
Page 3 of 10
Revision date: 11-Oct-2007
Version: 1.3

\_\_\_\_\_

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

**General Handling:** Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,

avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use

appropriate personal protective equipment (see Section 8).

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and

flames.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

**Eplerenone** 

Pfizer OEL TWA-8 Hr: 350 μg/m<sup>3</sup>

Titanium dioxide

 $= 10 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)** Australia TWA  $= 10 \text{ mg/m}^3 \text{ TWA}$ Austria OEL - MAKs  $= 6 \text{ mg/m}^3 \text{ MAK}$ = 10 mg/m<sup>3</sup> TWA **Belgium OEL - TWA Bulgaria OEL - TWA**  $= 10.0 \text{ mg/m}^3 \text{ TWA}$ **Denmark OEL - TWA** = 6 mg/m<sup>3</sup> TWA Estonia OEL - TWA = 5 mg/m<sup>3</sup> TWA France OEL - TWA  $= 10 \text{ mg/m}^3 \text{ VME}$ **Greece OEL - TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$  $= 5 \text{ mg/m}^3 \text{ TWA}$ 

 Ireland OEL - TWAs
 = 10 mg/m³ TWA

 = 4 mg/m³ TWA
 = 4 mg/m³ TWA

 Latvia OEL - TWA
 = 10 mg/m³ TWA

 Lithuania OEL - TWA
 = 5 mg/m³ IPRV

 Netherlands OEL - TWA
 = 10 mg/m³ MAC

Netherlands OEL - TWA = 10 mg/m³ MAC
OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

**Poland OEL - TWA** = 10.0 mg/m<sup>3</sup> NDS <2% free crystalline silica and containing no

asbestos

 Portugal OEL - TWA
 = 10 mg/m³ TWA

 Romania OEL - TWA
 = 10 mg/m³ TWA

 Spain OEL - TWA
 = 10 mg/m³ VLA-ED

 Sweden OEL - TWAs
 = 5 mg/m³ LLV

Ferric oxide red

ACGIH Threshold Limit Value (TWA) = 5 mg/m³ TWA Australia TWA = 5 mg/m³ TWA Austria OEL - MAKs = 6 mg/m³ MAK

**Material Name: Eplerenone Tablets** Page 4 of 10 Revision date: 11-Oct-2007

Version: 1.3

**Belgium OEL - TWA**  $= 5 \text{ mg/m}^3 \text{ TWA}$ **Bulgaria OEL - TWA**  $= 5.0 \text{ mg/m}^3 \text{ TWA}$ **Denmark OEL - TWA**  $= 3.5 \text{ mg/m}^3 \text{ TWA}$ Estonia OEL - TWA  $= 3.5 \text{ mg/m}^3 \text{ TWA}$ **Finland OEL - TWA** = 5 mg/m<sup>3</sup> TWA  $= 5 \text{ mg/m}^3 \text{ VME}$ France OEL - TWA **Greece OEL - TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$  $= 6 \text{ mg/m}^3 \text{ TWA}$ **Hungary OEL - TWA** Ireland OEL - TWAs  $= 10 \text{ mg/m}^3 \text{ TWA}$  $= 4 \text{ mg/m}^3 \text{ TWA}$  $= 5 \text{ mg/m}^3 \text{ TWA}$ Lithuania OEL - TWA

 $= 3.5 \text{ mg/m}^3 \text{ IPRV}$  $= 5 \text{ mg/m}^3 \text{ MAC}$ **Netherlands OEL - TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$ **OSHA - Final PELS - TWAs:**  $= 5 \text{ mg/m}^3 \text{ NDS}$ Poland OEL - TWA  $= 5 \text{ mg/m}^3 \text{ TWA}$ Portugal OEL - TWA Romania OEL - TWA  $= 5 \text{ mg/m}^3 \text{ TWA}$ Slovakia OEL - TWA  $= 1.5 \text{ mg/m}^3 \text{ TWA}$ = 5 mg/m<sup>3</sup> VLA-ED Spain OEL - TWA Sweden OEL - TWAs  $= 3.5 \text{ mg/m}^3 \text{ LLV}$ 

### Microcrystalline cellulose

**ACGIH Threshold Limit Value (TWA)** = 10 mg/m<sup>3</sup> TWA  $= 10 \text{ mg/m}^3 \text{ TWA}$ **Australia TWA Belgium OEL - TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$ Estonia OEL - TWA = 10 mg/m<sup>3</sup> TWA  $= 10 \text{ mg/m}^3 \text{ VME}$ France OEL - TWA  $= 10 \text{ mg/m}^3 \text{ TWA}$ Ireland OEL - TWAs  $= 4 \text{ mg/m}^3 \text{ TWA}$ 

Latvia OEL - TWA = 2 mg/m<sup>3</sup> TWA  $= 15 \text{ mg/m}^3 \text{ TWA}$ **OSHA - Final PELS - TWAs:** 

total  $= 5 \text{ mg/m}^3 \text{ TWA}$  $= 10 \text{ mg/m}^3 \text{ TWA}$ Portugal OEL - TWA

Romania OEL - TWA  $= 10 \text{ mg/m}^3 \text{ TWA}$ = 10 mg/m<sup>3</sup> VLA-ED Spain OEL - TWA

### Polyethylene glycol

Austria OEL - MAKs  $= 1000 \text{ mg/m}^3 \text{ MAK}$ Germany - TRGS 900 - TWAs  $= 1000 \text{ mg/m}^3 \text{ TWA}$ = 1000 mg/m<sup>3</sup> MAC **Netherlands OEL - TWA** Slovakia OEL - TWA  $= 1000 \text{ mg/m}^3 \text{ TWA}$ Slovenia OEL - TWA = 1000 mg/m<sup>3</sup> TWA

### Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m<sup>3</sup> Pfizer STEL 0.75 mg/m<sup>3</sup>

## Talc (non-asbestiform)

**ACGIH Threshold Limit Value (TWA)** = 2 mg/m<sup>3</sup> TWA particulate matter containing no asbestos and

Listed

<1% crystalline silica

**ACGIH OELs - Notice of Intended Changes** 

**Australia TWA**  $= 2.5 \text{ mg/m}^3 \text{ TWA}$ containing no asbestos fibers

asbestos-free fibers **Austria OEL - MAKs** = 2 mg/m<sup>3</sup> MAK

**Belgium OEL - TWA**  $= 2 \text{ mg/m}^3 \text{ TWA}$ 

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Version: 1.3

**Bulgaria OEL - TWA** = 1.0 f/cm3 TWA containing <2% uncombined crystalline silicon

dioxide

= 3.0 mg/m<sup>3</sup> TWA = 6.0 mg/m<sup>3</sup> TWA

Czech Republic OEL - TWA = 10 mg/m³ TWA = 2.0 mg/m³ TWA

= 2.0 mg/m³ TWA

Denmark OEL - TWA = 0.3 fiber/cm3 TWA

Estonia OEL - TWA = 0.5 mg/m³ TWA

= 1 mg/m³ TWA

Finland OEL - TWA = 0.5 fibers/cm3 TWA = 5 mg/m³ TWA

Greece OEL - TWA =  $10 \text{ mg/m}^3 \text{ TWA}$ =  $2 \text{ mg/m}^3 \text{ TWA}$ Hungary OEL - TWA =  $2 \text{ mg/m}^3 \text{ TWA}$ 

Ireland OEL - TWAs $= 0.8 \text{ mg/m}^3 \text{ TWA}$ Netherlands OEL - TWA $= 10 \text{ mg/m}^3 \text{ TWA}$ OSHA - Final PELs - Table Z-3 Mineral D:= 20 mppcf TWA

Poland OEL - TWA = 1.0 mg/m³ NDS = 4.0 mg/m³ NDS

Portugal OEL - TWA = 2 mg/m³ TWA

Romania OEL - TWA = 2 mg/m³ TWA

**Spain OEL - TWA** = 2 mg/m³ VLA-ED this value is for the particulated matter that is

free from asbestos and contains less than 1% of crystalline silica

Sweden OEL - TWAs =  $1 \text{ mg/m}^3 \text{ LLV}$ =  $2 \text{ mg/m}^3 \text{ LLV}$ 

Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m<sup>3</sup> TWA except stearates of toxic metals

Australia TWA $= 10 \text{ mg/m}^3 \text{ TWA}$ Belgium OEL - TWA $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Ireland OEL - TWAs = 10 mg/m<sup>3</sup> TWA except lead stearate

Lithuania OEL - TWA = 3 mg/m<sup>3</sup> IPRV

**Portugal OEL - TWA** = 10 mg/m<sup>3</sup> TWA does not include stearates of toxic metals **Spain OEL - TWA** = 10 mg/m<sup>3</sup> VLA-ED not including stearates of toxic metals

Sweden OEL - TWAs = 5 mg/m<sup>3</sup> LLV

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

**Analytical Method:** Analytical method available for Eplerenone. Contact Pfizer Inc for further information.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** 

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Page 6 of 10

Version: 1.3

**Respiratory protection:** Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:TabletsColor:WhiteMolecular Formula:MixtureMolecular Weight:Mixture

# 10. STABILITY AND REACTIVITY

Stability: Stable at normal conditions

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

## 11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

Lactose

Rat Oral LD50 > 10 g/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD 50 50 mg/kg

Polysorbate 80

Rat Oral LD50 25 g/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg

**Eplerenone** 

Rat Oral Minimum Lethal Dose > 2000 mg/kg

Mouse Oral Minimum Symptomatic Dose > 300 mg/kg

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Page 7 of 10

Version: 1.3

\_\_\_\_\_

Dog Oral Minimum Symptomatic Dose 500 mg/kg

Hypromellose

Rat Oral LD50 > 10,000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Sodium lauryl sulfate

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

**Eplerenone** 

Eye Irritation Rabbit Minimal Skin Irritation Rabbit Mild

Skin Sensitization - GPMT Guinea Pig Negative

Polyethylene glycol

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

**Eplerenone** 

13 Week(s) Rat Oral 500 mg/kg/day LOAEL Kidney

13 Week(s) Dog Oral 1.5 mg/kg/day NOEL Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Eplerenone** 

Reproductive & Fertility-Males Rat Oral 1000 mg/kg/day LOAEL Fertility

Embryo / Fetal Development Rat Oral 1000 mg/kg/day LOAEL Maternal Toxicity, Fetotoxicity Embryo / Fetal Development Rabbit Oral 300 mg/kg/day LOAEL Maternal Toxicity, Fetotoxicity Embryo / Fetal Development Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

**Eplerenone** 

Bacterial Mutagenicity (Ames) Negative

Mammalian Cell Mutagenicity Mouse Lymphoma Negative

Chromosome Aberration Negative Unscheduled DNA Synthesis Negative

In Vitro Micronucleus Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Eplerenone** 

6 Month(s) Mouse Oral 1000 mg/kg/day NOEL Not carcinogenic 2 Year(s) Male Rat Oral 75 mg/kg/day LOEL Benign tumors, Thyroid

2 Year(s) Female Rat Oral 250 LOEL Benign tumors, Thyroid

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Page 8 of 10

Version: 1.3

\_\_\_\_\_

Carcinogen Status: See below

Talc (non-asbestiform)

IARC: Group 3

Titanium dioxide

IARC: Group 2B OSHA: Present

Ferric oxide red

IARC: Group 3

# 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided. See Aquatic toxicity data of the active ingredient, below:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Eplerenone** 

Daphnia magna (Water Flea) TAD EC50 48 Hours > 380 mg/L

Pimephales promelas (Fathead Minnow) TAD LC50 96 Hours > 370 mg/L

Pseudokirchneriella subcapitata (Green Alga) OECD EbC50 72 Hours 0.24 mg/L

Pseudokirchneriella subcapitata (Green Alga) TAD NOEC 12 Days 10 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum

dose tested.

Bacterial Inhibition: (Species, Method, End Point, Duration, Result)

**Eplerenone** 

Bacteria OECD EC50 3 Hours > 1000 mg/L

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Page 9 of 10

Version: 1.3

## 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

### **OSHA Label:**

Non-hazardous in accordance with international standards for workplace safety.

### **Canada - WHMIS: Classifications**

### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

## **Eplerenone**

Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

Hypromellose

Inventory - United States TSCA - Sect. 8(b)XUAustralia (AICS):PresentStandard for the Uniform SchedulingSchedule 4

for Drugs and Poisons:

Titanium dioxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

236-675-5

Polysorbate 80

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Ferric oxide yellow

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentStandard for the Uniform Scheduling<br/>for Drugs and Poisons:Schedule 2Schedule 4

Schedule 5 Schedule 6

EU EINECS/ELINCS List 257-098-5

Ferric oxide red

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 4
Schedule 5
Schedule 6

Material Name: Eplerenone Tablets

Revision date: 11-Oct-2007

Page 10 of 10

Version: 1.3

EU EINECS/ELINCS List 215-168-2

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS): Present

EU EINECS/ELINCS List 232-674-9

Croscarmellose sodium

Australia (AICS): Present

Polyethylene glycol

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Sodium lauryl sulfate

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS/ELINCS List205-788-1

Lactose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS/ELINCS List

200-559-2

Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS/ELINCS List238-877-9

EEC No. 456-230-0

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS/ELINCS List

209-150-3

## 16. OTHER INFORMATION

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12

- Ecological Information.

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

### **End of Safety Data Sheet**